United Kingdom-based GlaxoSmithKline (GSK) plc has offered its technology license for its clinical-stage Ebola vaccines to the Sabin Vaccine Institute, a United States-based non-profit organisation that promotes global vaccine development, it was reported yesterday.
The contracts between both firms have been signed for progressing the development of the prophylactic candidate Ebola vaccines against the Ebola Zaire, Ebola Sudan and the Marburg virus. According to the contracts, Sabin has also acquired certain patent rights regarding the Ebola vaccines. The three candidate vaccines were developed initially through a partnership between the US National Institutes of Health and Okairos that was acquired by GSK in 2013. GSK says that the three ChAd3-based vaccines have so far shown a strong safety profile and promising immunogenicity results after being administered to over 5,000 adults and 600 children, in 13 different clinical trials.
GSK Vaccines chief medical officer, Thomas Breuer, said, 'These agreements with the Sabin Vaccine Institute are an important next step in the fight against Ebola and Marburg viruses. Enabling Sabin to build on the scientific progress GSK has delivered up to Phase II increases the likelihood these candidate vaccines may help prevent potential future outbreaks, and exemplifies GSK's approach to global health vaccines which supports partners in taking forward our innovations in a sustainable way.'
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer